Responsibility. For each of the [[Unknown Identifier]] and ​ Programs, following the completion of the applicable [[Unknown Identifier]] Technology Transfer or ​ Technology Transfer, # Acadia shall be solely responsible, at its sole expense, for all regulatory activities necessary to obtain and maintain Regulatory Approval of the applicable Licensed Products in the Field in the Territory, and # Acadia will own all Regulatory Materials for such Licensed Products in the Field in the Territory, including all Regulatory Approvals, and will be responsible for the payment of fees and all other associated regulatory costs for such Licensed Products in the Field in the Territory.

Responsibility. Subject to the terms and conditions of this Agreement, Acadia (and its Affiliates and Sublicensees, as applicable) shall be responsible, at its sole cost and expense, for the Commercialization of all Licensed Products in the Field in the Territory.

Responsibility. All payments under or in connection with this Agreement shall be inclusive of any Taxes and each Party shall be responsible for and shall bear, pay or set-off its own Taxes assessed by a tax or other authority except as otherwise set forth in this Agreement.

Responsibility. It is understood and agreed that searching for, identification and evaluation of Third Party Patents that may apply to any Excluded Technology or Sequence IP, including Patents that apply Program-Benefited Antibodies and Products based on sequence, Target, methods of treatment using any Program-Benefited Antibodies, or the like is the responsibility of [[Alector:Organization]], and that [[Adimab:Organization]] will have no responsibility for the foregoing nor liability if any such Third-Party Patents exist; provided, however, that the foregoing shall not diminish or otherwise mitigate [[Adimab:Organization]]’s obligations under [Section 7.2(e)] (No Incorporation of Proprietary Technology).

Responsibility. Neurocrine shall be solely responsible, at its sole expense, for the manufacture of all Compounds and Products for use under this Agreement, except as expressly set forth herein (including Material transferred by Xenon under [Section 4.10] and Inventory transferred under [Section 6.11]) or agreed by the Parties in writing. Exhibit O sets forth Xenon’s agreements with Third Party contract manufacturers for the manufacture and supply of Compounds and Products as in existence as of the Effective Date. The Parties will determine whether such agreements will be assigned to Neurocrine or whether Xenon will supply to Neurocrine any materials manufactured thereunder. If the Parties agree that Xenon will supply to Neurocrine any Compound or Product manufactured by Xenon’s Third Party contract manufacturer for use in any Clinical Trial, the Parties shall enter into a commercially reasonable supply agreement and associated quality agreement, under which Neurocrine shall purchase such Compound or Product at a price equal to Xenon’s internal costs (at the FTE Rate) and out-of-pocket costs to manufacture such Compound or Product. Notwithstanding anything in this Agreement to the contrary, this [Section 6.12] shall not constitute an agreement to transfer or assign any agreements by Xenon or any of its Affiliates if an attempted transfer or assignment thereof, without the consent of a Third Party, would constitute a breach or other contravention under any agreement to which Xenon or any of its Affiliates are a party.

Responsibility. A designated Party or its relevant Affiliate will be responsible for # Manufacturing clinical supplies of a Product as determined by the Manufacturing Working Group and # Manufacturing commercial supplies of a Product. The designated Party shall be [[Organization A:Organization]] or its relevant Affiliate unless otherwise agreed to by the Parties after holding good faith discussions regarding which Party is best positioned to serve in the function during the negotiation of the Joint Development & Commercialization Agreement as set forth in Section 4.1.1 of the Research Collaboration Agreement.

Responsibility. Except as otherwise provided in this Agreement, CANbridge will be ​. LogicBio will, and will cause its Affiliates to, ​.

Responsibility. In order to enable the Parties to consummate the transactions as contemplated under this Agreement in a timely manner, the Purchaser shall undertake and shall cause (steht dafür ein) its Affiliates to take any and all steps reasonable to obtain the Clearances at the earliest possible date and to avoid or eliminate each and every procedural impediment under any antitrust, competition or trade regulation law asserted by any Governmental Authority in writing. In particular, the Purchaser shall offer, and undertake that its Affiliates offer, upon request of the Seller, to the Governmental Authorities the acceptance of any obligations or conditions (Auflagen oder Bedingungen) imposed by any Governmental Authority, the compliance therewith and the making and satisfying of any commitments (Zusagen) as promptly as practicable, to the extent these are reasonable and do not materially adversely impact the Purchaser's business or the Group's Business as presently conducted, and the entrance into such other arrangements, as are reasonably necessary or desirable to avoid that the consummation of the transactions contemplated under this Agreement is materially delayed or prohibited.

Responsibility. Except as otherwise provided in this Agreement, Vertex will be solely responsible for, and will have sole and exclusive control over, the Research and Development of Products.

Responsibility. Apellis shall use Commercially Reasonable Efforts to oversee the activities of its Vendors. For clarity, Apellis will remain primarily responsible for all its obligations under this Agreement, notwithstanding any delegation to an Affiliate or a CRO and/or contracting with a Vendor, as if Apellis had not so delegated and/or contracted with respect to such responsibilities.